Please provide your email address to receive an email when new articles are posted on . The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with ...

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma BV combined with Len + R demonstrated ...

(RTTNews) - Pfizer Inc. (PFE) announced Tuesday that its Phase 3 study of the antibody-drug conjugate ADCETRIS (brentuximab vedotin) in combination with lenalidomide and rituximab showed positive ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

A retrospective multicentre analysis found that brentuximab vedotin (BV) with radiotherapy achieved complete or partial remission in 93% of patients with CD30-positive cutaneous T-cell lymphoma (CTCL) ...

Brentuximab vedotin with CHP is effective and safe for first-line PTCL treatment, achieving an 80% overall response rate. Median progression-free survival was 39.7 months, with a 1-year overall ...

- Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) resulted in longer progression ...

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma The ideas and opinions expressed in ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...